When

Tuesday, October 20, 2026

5:30 AM-7:30 AM PT

WheRE

Phoenix, AZ

Room: Phoenix Ballroom C

Sheraton Phoenix Downtown

faculty
Professor Tom Wilkinson, MA Cantab, MBBS, PhD, FRCP, FERS
Professor of Respiratory Medicine
Associate Dean Faculty of Medicine
University of Southampton
Honorary Consultant
University Hospital Southampton NHS Foundation Trust
Senior Investigator
National Institute for Health and Care Research
Senior Clinical Lead
National Respiratory Audit Programme
Southampton, United Kingdom

Registration & Breakfast @ 5:30AM (MST) (Breakfast provided).

Prefer to participate online? Register for our livestream at www.exchangecme.com/IL33PHXStream

This symposium is not supported, endorsed, or accredited by CHEST, unless otherwise noted.

There is no fee to attend this educational program; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

Program Description

Join us for this live educational symposium that brings interleukin (IL)-33, an emerging therapeutic target in respiratory medicine, to center stage. This program will examine the evolving role of IL-33 as both a driver of inflammation and a regulator of gene expression, highlighting its signaling pathways and contribution to the pathophysiology of chronic respiratory disease and acute infection. Attendees will gain insight into the scientific rationale for targeting IL-33 in therapeutic development, along with the latest updates from ongoing clinical investigations of biologic agents designed to modulate its activity. Our expert panel will share their perspectives through dynamic discussion and real-time engagement with the audience.

Target Audience

This educational activity has been designed to educate pulmonologists, as well as critical care, infectious disease, and emergency medicine clinicians who manage patients with chronic obstructive pulmonary disease (COPD) or acute respiratory infections.

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  1. Explain the pathophysiologic roles of IL-33 signaling in COPD and acute respiratory infections
  2. Compare the pharmacologic profiles and published evidence for emerging biologic therapies targeting IL-33 for COPD and acute respiratory infections
  3. Integrate emerging biologic therapies into treatment algorithms for COPD or acute respiratory infections as they become available

Program Agenda:

5:30AM Breakfast and Registration

6:00AM – 7:30AM Program

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation. 

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Americans With Disabilities Act

Any activity registrant who feels s/he may need accommodation based on the impact of a disability should contact Integritas at info@exchangecme.com to discuss their specific needs.

Integritas Contact Information

For information about this program, please contact us at info@exchangecme.com.

Register Now

attend event
Related events
OCT
10
2026
Science in the Spotlight
1.50 CME

Eosinophilic Esophagitis in the Spotlight

Epithelial Cytokines from Disease Pathogenesis to Biologic Treatment

Time: 6:00 PM-7:30 PM CT
Venue: ACG - Omni Nashville Hotel
Location: Omni Nashville - Nashville, TN
Faculty: Evan Dellon, MD, MPH; Maureen Bauer, MD; Girish Hiremath, MD, MPH
OCT
10
2026
Science in the Spotlight
1.50 CME

Eosinophilic Esophagitis in the Spotlight

Epithelial Cytokines from Disease Pathogenesis to Biologic Treatment

Time: 6:00 PM-7:30 PM CT
Venue: Online - Virtual Live Stream
Location: Online - Virtual Live Stream
Faculty: Evan Dellon, MD, MPH; Maureen Bauer, MD; Girish Hiremath, MD, MPH
OCT
20
2026
Mechanisms to Medicine
1.50 CME

New Avenues in Hypertension

Evolving Management of Uncontrolled and Resistant Disease

Time: 8:30 AM-10:00 AM CT
Venue: AAFP FMX - Omni Nashville Hotel
Location: Omni Nashville - Nashville, TN
Faculty: John M. Flack, MD, MPH; Kausik Umanath, MD, MS, FACP, FASN; Karol Watson, MD, PhD
OCT
20
2026
Mechanisms to Medicine
1.50 CME

New Avenues in Hypertension

Evolving Management of Uncontrolled and Resistant Disease

Time: 8:30 AM-10:00 AM CT
Venue: Online - Virtual Live Stream
Location: Online - Virtual Live Stream
Faculty: John M. Flack, MD, MPH; Kausik Umanath, MD, MS, FACP, FASN; Karol Watson, MD, PhD